guest ::
| Home > Publications database > VUV spectroscopy of $Ca_3Sc_2Si_3O_12:Pr^{3+}$: scintillator optimization by co-doping with $Mg^{2+}$ |
| Home > Publications database > VUV spectroscopy of $Ca_3Sc_2Si_3O_12:Pr^{3+}$: scintillator optimization by co-doping with $Mg^{2+}$ |
| Journal Article | PHPPUBDB-25115 |
; ; ; ; ; ;
2012
ECS
Pennington, NJ
This record in other databases: 
Please use a persistent id in citations: doi:10.1149/2.009205jss
Abstract: This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.
Keyword(s): Adolescent (MeSH) ; Adult (MeSH) ; Anticonvulsants: therapeutic use (MeSH) ; Child (MeSH) ; Child, Preschool (MeSH) ; Double-Blind Method (MeSH) ; Drug Evaluation (MeSH) ; Drug Therapy, Combination: methods (MeSH) ; Epilepsy: drug therapy (MeSH) ; Female (MeSH) ; Humans (MeSH) ; Longitudinal Studies (MeSH) ; Male (MeSH) ; Treatment Outcome (MeSH) ; Triazoles: therapeutic use (MeSH) ; Young Adult (MeSH) ; Anticonvulsants ; Triazoles ; rufinamide
; No Author Disambiguation
|
The record appears in these collections: |
PDF
PDF (PDFA)